Hemogenyx Pharmaceuticals (LON:HEMO) Releases Earnings Results

Hemogenyx Pharmaceuticals (LON:HEMO) announced its earnings results on Monday. The company reported GBX (101.70) earnings per share (EPS) for the quarter, Digital Look Earnings reports.

Hemogenyx Pharmaceuticals Trading Down 0.8%

LON HEMO opened at GBX 474.74 on Tuesday. The company has a debt-to-equity ratio of 167.66, a quick ratio of 6.72 and a current ratio of 1.38. The firm has a market cap of £32.28 million, a PE ratio of -2.78 and a beta of 1.49. Hemogenyx Pharmaceuticals has a one year low of GBX 356 and a one year high of GBX 1,345. The firm’s fifty day moving average is GBX 575.01 and its two-hundred day moving average is GBX 734.08.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.